SAN FRANCISCO--(BUSINESS WIRE)--Gemmus Pharma Inc. ("Gemmus") will present results from its initial studies designed to evaluate the use of GP1001 in influenza at the 26th International Conference on Antiviral Research (ICAR) in San Francisco on May 13 in the afternoon session. The talk, titled “GP1001: a host targeted influenza therapy,” will be given by Daryl Faulds, Ph.D., Co-Founder and Chief Executive Officer of Gemmus, a privately held drug development company.
The company’s candidate, GP1001, is an orally available eicosanoid being developed for the treatment of moderate to severe symptoms of influenza infection. GP1001 is believed to work by down-regulating the cytokine induced post-viral inflammatory response, as opposed to having activity as a primary antiviral agent. Results of the trials demonstrate that influenza-infected mice that were treated with GP1001 were protected against death compared to placebo-treated mice. The increased survival was due to a decrease in respiratory tract inflammation as demonstrated by a decrease in lung weight, lung score and pro-inflammatory cytokines in influenza infected lungs.
“The ability to control the post-infection cytokine mediated pathophysiology, especially if ultimately combined with known direct antivirals, might result in a clinically meaningful advance in our ability to treat influenza infections,” said Marc Rubin, MD, a member of the Gemmus Board of Directors.
There are no medications approved for the treatment of influenza other than neuraminidase inhibitors and amantadines, the latter having recognized drug resistance issues. GP1001 represents a new and potentially groundbreaking approach to improved influenza therapies that focus on managing the immune system to reduce the symptoms of the infection. By reducing, but not eliminating, the level of pro-inflammatory cytokines in the lung, GP1001 and related compounds under development are “strain-agnostic” – they can treat infections even from influenza that has become drug resistant. This new approach to treating the flu allows for faster return to normal activities than is possible with no treatment or with administration of antiviral therapies.
Gemmus is a privately held biotechnology company developing innovative pharmaceutical products for the treatment of infectious diseases by focusing on modulating the host response to disease. Gemmus was founded in 2007 to develop novel treatments for influenza based on EP2 and EP4 agonists, and in-licensed technology from a major pharmaceutical company. Gemmus has received SBIR(NIH) and QTDP competitive grants and is funded by a syndicate of angel groups led by the Life Science Angels (LSA). Gemmus is a member of the QB3 network, a San Francisco Bay Area Biotech incubator associated with UCSF Mission Bay campus. For more information and corporate background, please visit: www.gemmuspharma.com.
Forward Looking Statements
Statements included in this press release that are not a description of historical facts may be forward looking statements. The inclusion of forward looking statements should not be regarded as a representation by Gemmus that any of its plans will be achieved. Actual results may differ materially from those anticipated or set forth in this press release due to the risks and uncertainties inherent in Gemmus' business including, without limitation, statements about difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products, unexpected performance or side effects of its products, the scope and validity of its products’ patent protection, competition from other companies and its ability to obtain additional financing to support its operations. All forward looking statements are qualified in their entirety by this statement and Gemmus undertakes no obligation to revise or update this press release to reflect events or circumstances occurring after the date hereof.